Xencor, Inc. Common Stock
XNCR US98401F1057
Xencor Inc is a clinical-stage biopharmaceutical company based in the United States. It focuses on discovering and developing engineered monoclonal antibody and other protein therapeutics to treat severe and life-threatening diseases such with unmet medical needs. The company uses its XmAb technology platform to create antibody product candidates such as XmAb5871 and XmAb7195. It also has a few pre-clinical stage candidates in its portfolio such as XmAb14045, XmAb662 among others. It earns its revenue from research and development collaborations and licenses of its internally developed drug candidates.
Annual Performance 1
| 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -8% | -37% | -18% | 2% | 1% |
Annual Insiders Turnover, USD 2
1 annual and historical performance metrics are recalculated on a daily basis;
2 represents the total value of insider transactions (both buying and selling);
Insider Activity
| Person | Price | Shares | Total | Published | Completed |
|---|---|---|---|---|---|
| Ranieri Richard J |
9.22 USD |
2,993 Sold |
27,595 USD |
12/06/2025 | 16/06/2025 |
| Gustafson Kurt A |
9.22 USD |
2,993 Sold |
27,595 USD |
12/06/2025 | 16/06/2025 |
| Montgomery Alan Bruce |
9.22 USD |
2,215 Sold |
20,422 USD |
12/06/2025 | 16/06/2025 |
| Montgomery Alan Bruce |
9.22 USD |
2,215 Sold |
20,422 USD |
12/06/2025 | 16/06/2025 |
| Gorman Kevin Charles |
9.22 USD |
3,173 Sold |
29,255 USD |
12/06/2025 | 16/06/2025 |
| Montgomery Alan Bruce |
9.22 USD |
2,215 Sold |
20,422 USD |
12/06/2025 | 16/06/2025 |
| Feigal Ellen |
9.22 USD |
2,993 Sold |
27,595 USD |
12/06/2025 | 16/06/2025 |
| Valente Nancy EX VP |
11.03 USD |
4,616 Sold |
50,914 USD |
02/05/2025 | 02/05/2025 |
| Cornelissen Bart Jan VP |
8.06 USD |
3,750 Sold |
30,233 USD |
10/04/2025 | 10/04/2025 |
| Dahiyat Bassil I CEO |
13.60 USD |
19,716 Sold |
268,080 USD |
10/03/2025 | 10/03/2025 |